

1/30




FIG. 1A





FIG. 1B

2/30



Expected mass of EphA2 proteins

Full-length: 114 kDa


EphA2 CO: 52 kDa

EphA2 EX2: 62 kDa


Ab: Rabbit anti-EphA2 (carboxy terminus-specific) polyclonal antibody

FIG.2

3/30




4/30

**FIG.4**

5/30

Human EphA2 Expression in CT26 Subclones  
Generation of "the Super Clone"




- Subclones of transfected clones obtained by FACS sorting into 96 well plates

FIG. 5

6/30

**Human EphA2 Protein Expression in  
CT26 Murine Colon Carcinoma Cells  
Following FACS Sorting**



**FIG. 6**

7/30

Human EphA2 Protein Expression in B16F10 Cells  
Round 3

Anti-EphA2 + 2° (mean = 42.4)

2°-control (mean = 5.58)

Unstained (mean = 4.73)





FIG. 7

8/30



Ab: Rabbit anti-EphA2 (carboxy terminus-specific) polyclonal antibody

**FIG.8**

9/30




FIG. 9A



FIG. 9B

10/30




FIG. 10A

11/30




FIG. 10B




FIG. 11A

Effect of *L. monocytogenes* Expressing ECD of huEphA2 on  
CT26 huEphA2 Tumor Growth  
Prevention Study






FIG. 11B



15/30



16/30




FIG. 12

17/30

**Effect of *L. monocytogenes* Expressing ECD of huEphA2 on CT26 Tumor Growth Therapeutic Study**




FIG. 13A

**Effect of *L. monocytogenes* Expressing ECD of huEphA2 CT26 Tumor Growth Therapeutic Study**





FIG. 13B

19/30



20/30




FIG. 14A

21/30




FIG. 14B

22/30




FIG. 14C

23/30




FIG. 14D

24/30




FIG. 14E

25/30




FIG. 14F

26/30




FIG. 15

27/30





FIG. 16

28/30



29/30




FIG.18A




FIG. 18B